Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
Metadatos
Afficher la notice complèteAuteur
García Pinel, Beatriz; Porras Alcalá, Cristina; Ortega Rodríguez, Alicia; Sarabia, Francisco; Prados Salazar, José Carlos; Melguizo Alonso, Consolación; López Romero, Juan ManuelEditorial
MDPI
Materia
Lipid-based nanoparticles Drug release Drug resistance Clinical trials Cancer
Date
2019-04-19Referencia bibliográfica
García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., & López-Romero, J. M. (2019). Lipid-based nanoparticles: application and recent advances in cancer treatment. Nanomaterials, 9(4), 638.
Patrocinador
This work was supported by Consejería de Salud de la Junta de Andalucía (project PI-0476-2016 and PI-0102-2017), by CICYT, Spain (project CTQ16-76311) and by FPU16/01716 (B. Garcia-Pinel) from Ministerio Ciencia, Innovación y Universidades.Résumé
Many therapeutically active molecules are non-soluble in aqueous systems, chemically
and biologically fragile or present severe side effects. Lipid-based nanoparticle (LBNP) systems
represent one of the most promising colloidal carriers for bioactive organic molecules. Their current
application in oncology has revolutionized cancer treatment by improving the antitumor activity of
several chemotherapeutic agents. LBNPs advantages include high temporal and thermal stability,
high loading capacity, ease of preparation, low production costs, and large-scale industrial production
since they can be prepared from natural sources. Moreover, the association of chemotherapeutic
agents with lipid nanoparticles reduces active therapeutic dose and toxicity, decreases drug resistance
and increases drug levels in tumor tissue by decreasing them in healthy tissue. LBNPs have been
extensively assayed in in vitro cancer therapy but also in vivo, with promising results in some clinical
trials. This review summarizes the types of LBNPs that have been developed in recent years and the
main results when applied in cancer treatment, including essential assays in patients.